Evidence map›Paper›PMID 38104219›Full record

ArticleBone marrow transplantation2024

Analysis of risk factors for fatal renal complications after allogeneic hematopoietic cell transplantation.

Ryu Yanagisawa, Hiroaki Koyama, Kimikazu Yakushijin, Naoyuki Uchida, Atsushi Jinguji, Wataru Takeda, Tetsuya Nishida, Masatsugu Tanaka, Tetsuya Eto, Hiroyuki Ohigashi and 11 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 17 institutions in 1 country.

Ryu YanagisawaDivision of Blood Transfusion, Shinshu University Hospital, Matsumoto, Japan. ryu@shinshu-u.ac.jp.ORCID 0000-0003-4012-0958
Hiroaki KoyamaDepartment of Hematology, Tokyo Women's Medical University, Tokyo, Japan.
Kimikazu YakushijinDepartment of Medical Oncology and Hematology, Kobe University Hospital, Kobe, Japan.ORCID 0000-0003-2511-7857
Naoyuki UchidaDepartment of Hematology, Federation of National Public Service Personnel Mutual Aid Associations TORANOMON HOSPITAL, Tokyo, Japan.ORCID 0000-0001-5952-5926
Atsushi JingujiHematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Wataru TakedaDepartment of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
Tetsuya NishidaDepartment of Hematology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Nagoya, Japan.
Masatsugu TanakaDepartment of Hematology, Kanagawa Cancer Center, Yokohama, Japan.
Tetsuya EtoDepartment of Hematology, Hamanomachi Hospital, Fukuoka, Japan.
Hiroyuki OhigashiDepartment of Hematology, Hokkaido University Hospital, Sapporo, Japan.
Kazuhiro IkegameDepartment of Hematology, Hyogo Medical University Hospital, Nishinomiya, Japan.ORCID 0000-0002-5421-7470
Ken-Ichi MatsuokaDepartment of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.ORCID 0000-0001-7955-8266
Yuta KatayamaDepartment of Hematology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan.ORCID 0000-0001-5054-9104
Yoshinobu KandaDivision of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.ORCID 0000-0002-4866-9307
Masashi SawaDepartment of Hematology and Oncology, Anjo Kosei Hospital, Anjo, Japan.
Toshiro KawakitaDepartment of Hematology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan.
Makoto OnizukaDepartment of Hematology/Oncology, Tokai University School of Medicine, Isehara, Japan.ORCID 0000-0003-3864-0823
Takahiro FukudaDepartment of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
Yoshiko AtsutaJapanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan.ORCID 0000-0003-4404-2870
Akihito ShinoharaDepartment of Hematology, Tokyo Women's Medical University, Tokyo, Japan.ORCID 0000-0002-5530-6133
Hideki NakasoneDivision of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.ORCID 0000-0001-5812-9315
Jichi Medical University · JPTokyo Women's Medical University · JPAichi Medical University · JPAnjo Kosei Hospital · JPHamanomachi Hospital · JPHiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital · JPHokkaido University Hospital · JPHyogo University · JPJapanese Red Cross Nagoya Daiichi Hospital · JPKanagawa Prefectural Hospital Organization · JPKobe University Hospital · JPKumamoto Medical Center · JPOkayama University Hospital · JPShinshu University Hospital · JPTokai University · JPTokyo Metropolitan Komagome Hospital · JPToranomon Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Various complications can influence hematopoietic cell transplantation (HCT) outcomes. Renal complications can occur during the early to late phases of HCT along with various factors. However, studies focusing on fatal renal complications (FRCs) are scarce. Herein, we analyzed 36,596 first allogeneic HCT recipients retrospectively. Overall, 782 patients died of FRCs at a median of 108 (range, 0-3,440) days after HCT. The cumulative incidence of FRCs was 1.7% and 2.2% at one and five years, respectively. FRCs were associated with older age, male sex, non-complete remission (non-CR), lower performance status (PS), and HCT comorbidity index (HCT-CI) associated with renal comorbidity in multivariate analysis. The risk factors within 100 days included older age, multiple myeloma, PS, and HCT-CI comorbidities (psychiatric disturbance, hepatic disease, obesity, and renal disease). Older age and male sex were risk factors between 100 days and one year. After one year, HCT-CI was associated with the presence of diabetes and prior solid tumor; total body irradiation was identified as a risk factor. Non-CR was a common risk factor in all three phases. Furthermore, acute and chronic graft-versus-host disease, reactivation of cytomegalovirus, and relapse of underlying disease also affected FRCs. Systematic follow-up may be necessary based on the patients' risk factors and post-HCT events.

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansMaleNeoplasm Recurrence, LocalRetrospective StudiesRisk FactorsTransplantation ConditioningTransplantation, Homologous

Identifiers

PMID38104219
OpenAlexW4389832013

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.